What is in a pericapsular solution and where is it injected in a patient with significant joint pain, possibly due to osteoarthritis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 13, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Pericapsular Solution Composition and Injection Site

A pericapsular solution typically contains a local anesthetic (such as bupivacaine or ropivacaine) combined with a corticosteroid, and is injected around the joint capsule rather than directly into the joint space itself. 1

Solution Components

The pericapsular injection solution generally includes:

  • Local anesthetic: Commonly bupivacaine, lidocaine (lignocaine), or mepivacaine at concentrations of 0.5-1% 1, 2
  • Corticosteroid: Methylprednisolone (40-80 mg for large joints), triamcinolone acetonide (40-80 mg), or similar long-acting corticosteroid preparations 3, 2
  • Total volume: Typically 4.5-5 ml for adequate distribution around the capsule 1, 4

Injection Location

Pericapsular injections are administered into the tissues surrounding the joint capsule, not into the intra-articular space. 1 This distinguishes them from intra-articular injections, which target the joint cavity itself.

Key Anatomical Considerations:

  • For hip joints: The injection is placed around the hip capsule, often targeting the pericapsular nerve group (PENG) region, which lies between the psoas tendon and the pubic ramus 5
  • For knee joints: Pericapsular injections target the soft tissues and nerve structures around the joint capsule 1
  • For sacroiliac joints: The solution is delivered around the SI joint capsule when intra-articular access is challenging 4

Clinical Context and Efficacy

Important distinction: The evidence base strongly favors intra-articular over pericapsular injections for osteoarthritis pain management. 1

  • Intra-articular corticosteroid injections are recommended by major guidelines (VA/DoD 2020, EULAR 2017) for persistent knee and hip OA pain 1, 6
  • Pericapsular injections showed equivalent results to intra-articular injections in one study, but this is not the standard approach 1
  • For hip OA specifically, intra-articular triamcinolone (80 mg) provided significant pain relief at 3 and 12 weeks, while local anesthetic alone (pericapsular) showed no significant benefit 2

Evidence Comparison:

A critical study by Lilius et al. randomized 109 patients into three groups: intra-articular corticosteroid + anesthetic, pericapsular corticosteroid + anesthetic, and intra-articular saline. While both active treatment groups showed some benefit, the study design suggests pericapsular administration may have limited efficacy compared to intra-articular delivery. 1

Technical Administration

Ultrasound or fluoroscopic guidance is strongly recommended, particularly for hip injections, to ensure accurate placement and avoid inadvertent intra-articular or intravascular injection. 1, 6

  • Strict aseptic technique is mandatory 3
  • The suspension should be shaken before use and injected without delay to prevent settling 3
  • Care must be taken to avoid injecting into surrounding tissues, which may cause tissue atrophy 3

Clinical Caveat

For osteoarthritis-related joint pain, intra-articular injection remains the evidence-based standard, not pericapsular injection. 1, 6 Pericapsular approaches are primarily used for:

  • Nerve blocks for perioperative analgesia (e.g., PENG block for hip surgery) 7, 5
  • Cases where intra-articular access is technically difficult 4
  • Specific pain syndromes involving pericapsular structures rather than the joint itself 1

The emerging use of pericapsular nerve group (PENG) blocks with local anesthetic alone (without corticosteroid) shows promise for chronic hip pain, but this represents a different therapeutic approach focused on nerve blockade rather than anti-inflammatory effects. 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

[Injection of anaesthetic-corticosteroid to relieve sacroiliac joint pain after lumbar stabilisation].

Acta chirurgiae orthopaedicae et traumatologiae Cechoslovaca, 2011

Guideline

Intra-Articular Methylprednisolone Injection Guidelines for Osteoarthritis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Perineural Injections for Knee Pain Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the recommended oral corticosteroid (CS) dose for osteoarthritis (OA)?
What is the recommended initial treatment for osteoarthritis of the right hip in a patient with type 2 diabetes, hypertension, atrial fibrillation, peptic ulcer disease, alcohol use disorder, and obesity?
What is the best corticosteroid for intra-articular knee injection?
Can a Medrol (methylprednisolone) dose pack help with lumbago muscle spasms?
What are the next steps in managing a 54-year-old male patient with a history of right-hand second metacarpal fracture who reports intermittent pain between the 2nd and 3rd metacarpal heads?
What are the best books for an individual with low self-esteem?
What are the next steps for an adult patient with no significant medical history and lab results showing cancer?
What is the best approach to managing a patient with severe hypertension (blood pressure 170/100)?
What is the best course of action for an asymptomatic elderly female patient with a stable 3cm (centimeter) adrenal gland lesion, likely an adrenal adenoma, that has been present for several years?
What are the treatment options for skin manifestations in patients with inflammatory bowel disease (IBD)?
What is the next step in treatment for a patient with a KRAS (Kirsten rat sarcoma viral oncogene homolog) Q61R mutation and TP53 (tumor protein p53) mutation, microsatellite stability, and a non-mucinous tumor, who has achieved a 26% reduction in tumor size after 5 cycles of FOLFOX (folinic acid, fluorouracil, and oxaliplatin) and Avastin (bevacizumab)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.